To evaluate the benefits and costs of maralixibat within its marketing authorisation for treating type 2 progressive familial intrahepatic cholestasis for national commissioning by NHS England.
Status Proposed
Process HST
ID number 3818

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
01 March 2021 (14:00) Scoping workshop
08 January 2021 - 05 February 2021 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
08 January 2021 Draft scope documents

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance